# Phase 1/2 obesity trials recruiting: 23 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials in phase 1/2 for obesity that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 obesity trials: 23 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/obesity

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 23
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07940803 | A Research Study of a New Medicine NNC0662-3168 for Weight Management and Type 2 Diabetes | Novo Nordisk A/S | Phase 1/2 | Not yet recruiting | Overweight, Obesity, Type 2 Diabetes Mellitus | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940803) |
| October 27, 2026 | NCT07897383 | Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity | University Hospital, Gentofte, Copenhagen | Phase 1/2 | Not yet recruiting | Obesity & Overweight | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897383) |
| September 11, 2026 | NCT07815678 | First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671 | Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics | Phase 1/2 | Recruiting | Obesity | 164 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815678) |
| July 14, 2026 | NCT07702890 | A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and... | Gubra A/S | Phase 1/2 | Recruiting | Obesity, Type 2 Diabetes | 188 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07702890) |
| June 11, 2026 | NCT07642635 | Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy | Vanderbilt University Medical Center | Phase 1/2 | Recruiting | Duchenne Muscular Dystrophy (DMD) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07642635) |
| April 29, 2026 | NCT07557355 | A Study of SRSD384 in Overweight or Obese Participants | Sirius Therapeutics Co., Ltd. | Phase 1/2 | Not yet recruiting | Overweight , Obesity | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07557355) |
| March 11, 2026 | NCT07463846 | A Study to Evaluate ALN-2232 in Participants With Obesity | Alnylam Pharmaceuticals | Phase 1/2 | Recruiting | Obesity | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07463846) |
| February 9, 2026 | NCT07398404 | A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients | Medical University of South Carolina | Phase 1/2 | Not yet recruiting | Obesity, Smoking Cessation, Bariatric Surgery Patients | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07398404) |
| February 9, 2026 | NCT07395960 | The Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive Impairment | Fudan University | Phase 1/2 | Recruiting | Mild Cognitive Impairment, Overweight or Obesity, Elderly | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07395960) |
| January 13, 2026 | NCT07336862 | Bariatric Surgery Combined With GLP-1 Receptor Agonists Study | China-Japan Friendship Hospital | Phase 1/2 | Recruiting | Obesity | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07336862) |
| November 24, 2025 | NCT07245771 | Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as... | Ikaria Bioscience Pty Ltd | Phase 1/2 | Recruiting | Obesity &Amp; Overweight | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07245771) |
| November 21, 2025 | NCT07243171 | A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese... | Hangzhou Sciwind Biosciences Co., Ltd. | Phase 1/2 | Recruiting | Overweight and/or Obesity, Weight Management | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07243171) |
| June 24, 2025 | NCT07033767 | Exploring a Natural Solution for Childhood Obesity | Western University | Phase 1/2 | Not yet recruiting | Obesity, Children | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07033767) |
| April 22, 2025 | NCT06937203 | A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Arrowhead Pharmaceuticals | Phase 1/2 | Recruiting | Obesity, Diabetes Mellitus, Type 2 | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06937203) |
| February 24, 2025 | NCT06842186 | A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity | Wave Life Sciences USA, Inc. | Phase 1/2 | Recruiting | Overweight and Obesity | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06842186) |
| January 1, 2025 | NCT06755827 | Pilot Testing a Novel Approach to Pediatric Obesity Treatment | Texas Tech University | Phase 1/2 | Recruiting | Overweight Adolescents, Obese Adolescents | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06755827) |
| November 25, 2024 | NCT06703788 | Integrated Traditional Chinese Medicine Day Care Program for Metabolic Syndrome | Chang Gung Memorial Hospital | Phase 1/2 | Recruiting | Obesity, Metabolic Syndrome, Dyslipidemias, Diabetes Mellitus | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06703788) |
| April 3, 2024 | NCT06345560 | Pharmacokinetics of Drospirenone Only Pills: A Pre- and Post-Bariatric Surgery Study | Chulalongkorn University | Phase 1/2 | Recruiting | Contraception | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06345560) |
| August 2, 2023 | NCT05972564 | The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function | Vanderbilt University Medical Center | Phase 1/2 | Recruiting | Obesity, Metabolic Syndrome | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05972564) |
| February 27, 2023 | NCT05746039 | Feasibility of Semaglutide in Advanced Lung Disease | University of Pennsylvania | Phase 1/2 | Recruiting | Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary... | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05746039) |
| April 6, 2022 | NCT05312892 | Sympathetic Mechanisms in Obesity-Crossover Design | Vanderbilt University Medical Center | Phase 1/2 | Recruiting | Obesity, Hypertension | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05312892) |
| February 1, 2018 | NCT03418857 | Probiotics and Gut Health | Penn State University | Phase 1/2 | Recruiting | Metabolic Syndrome | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03418857) |
| October 2, 2017 | NCT03298334 | Vaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates. | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1/2 | Recruiting | Cesarean Delivery Affecting Newborn, Obesity, Childhood, Intestinal Microbiome, Microbiota, Host Microbial... | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03298334) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Vanderbilt University Medical Center | 3 |
| Penn State University | 1 |
| [Alnylam Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/alnylam-pharmaceuticals) | 1 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 1 |
| Wave Life Sciences USA, Inc. | 1 |
| Chang Gung Memorial Hospital | 1 |
| Texas Tech University | 1 |
| University of Pennsylvania | 1 |
| Ikaria Bioscience Pty Ltd | 1 |
| China-Japan Friendship Hospital | 1 |
| Western University | 1 |
| Fudan University | 1 |
| University Hospital, Gentofte, Copenhagen | 1 |
| [Arrowhead Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/arrowhead-pharmaceuticals) | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
| Chulalongkorn University | 1 |
| Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics | 1 |
| Sirius Therapeutics Co., Ltd. | 1 |
| Medical University of South Carolina | 1 |
| Hangzhou Sciwind Biosciences Co., Ltd. | 1 |
| Gubra A/S | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 11 |
| Australia | 3 |
| China | 3 |
| Canada | 1 |
| Moldova | 1 |
| Romania | 1 |
| United Kingdom | 1 |
| Taiwan | 1 |
| New Zealand | 1 |
| Thailand | 1 |
| Germany | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Textile manufacturers in the United States](https://specstream.ai/data/businesses/textile-manufacturers/united-states)
- [Occupational safety services in the United States](https://specstream.ai/data/businesses/occupational-safety-services/united-states)
- [Food and beverage exporters in the United States](https://specstream.ai/data/businesses/food-and-beverage-exporters/united-states)
- [Bottled water companies in the United States](https://specstream.ai/data/businesses/bottled-water-companies/united-states)
- [Telephone service providers in the United States](https://specstream.ai/data/businesses/telephone-service-providers/united-states)
- [Nigerian restaurants in the United States](https://specstream.ai/data/businesses/nigerian-restaurants/united-states)
